MEP5709A - 4-phenyl-pyridine derivatives - Google Patents

4-phenyl-pyridine derivatives

Info

Publication number
MEP5709A
MEP5709A MEP-57/09A MEP5709A MEP5709A ME P5709 A MEP5709 A ME P5709A ME P5709 A MEP5709 A ME P5709A ME P5709 A MEP5709 A ME P5709A
Authority
ME
Montenegro
Prior art keywords
lower alkyl
hydrogen
group
halogen
phenyl
Prior art date
Application number
MEP-57/09A
Other languages
English (en)
Croatian (hr)
Inventor
Bos Michael
Branca Quirico
Galley Guido
Godel Thieerry
Hoffmann Huwyler Torsten
Hunkeler Walter
Schnider Patrick
Stadle Heinz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MEP5709A publication Critical patent/MEP5709A/xx
Publication of ME00593B publication Critical patent/ME00593B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja opšte formule u kojoj označavaju R vodonik, niži alkil, niži alkoksi, halogen trifl uormeti l, R1 vodonik ili halogen, R i R1 mogu zajedno formirati -CH=CH-CH=CH-, R2 i R2’ nezavisno jedan od drugog označavaju vodonik, halogen, trifl uormeti l, niži alkoksi ili cijan-grupu, ili R2 i R2’ mogu zajedno formirati grupu -CH=CH-CH=CH- koja je opciono supsti tuisana sa jednim ili dva supsti tuenta odabrana izmedu nižeg alkila ili niže alkoksi-grupe, R3 vodonik, niži alkil ili formira cikloalkil-grupu, R4 vodonik, -N(R5)2, -N(R5)(CH2),OH, -N(R5)S(0)2- niži alkil, -N(R5)S(0)2-fenil, -N=CH-N(R5)2, -N(R5)C(0)R5 ili ciklični tercijarni amin grupe R5 nezavisno jedan od drugog označava vodonik, C3_6-cikloalkil, benzil iii niži alkil, R6 vodonik, hidroksi, niži alkil, -(CH2),C00-niŽi alkil, -N(R5)CO-niži alkil, hidroksi-niži alkil, cijan, -(CH2)nO(CH2)n0H, -CHO ili petočalanu ili šestočanu heterocikličonu grupu koja je opciono vezana preko alkilenske grupe, X -C (0) N(R5)-, - (CH2).0-, - (CH2)mN (R5) -,N (R5) C (0) ili -N (R5) (CH2)m-, n 0-4 im 1 ili 2, i na njihove farmaceutski prihvatljive kiselinske adicione soli. Jedinjenja formule I pokazuju visok afi nitet prema NK-1 receptoru. Ona se mogu primeniti za le’aenje bolesti koje su u vezi sa antagonisti ma NK-1 receptora.
MEP-2009-57A 1999-02-24 2000-02-22 Derivati 4-fenil-piridina ME00593B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (2)

Publication Number Publication Date
MEP5709A true MEP5709A (en) 2011-12-20
ME00593B ME00593B (me) 2015-08-31

Family

ID=26152908

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-57A ME00593B (me) 1999-02-24 2000-02-22 Derivati 4-fenil-piridina

Country Status (55)

Country Link
US (2) US6297375B1 (bs)
EP (2) EP1394150B1 (bs)
JP (1) JP3399900B2 (bs)
KR (1) KR100384904B1 (bs)
CN (1) CN1142144C (bs)
AR (2) AR029614A1 (bs)
AT (2) ATE277905T1 (bs)
AU (1) AU767048B2 (bs)
BE (1) BE2015C057I2 (bs)
BG (1) BG64554B1 (bs)
BR (1) BRPI0000908B8 (bs)
CA (1) CA2299139C (bs)
CY (3) CY1111317T1 (bs)
CZ (1) CZ300596B6 (bs)
DE (3) DE60045564D1 (bs)
DK (2) DK1394150T3 (bs)
EA (1) EA003673B1 (bs)
EG (1) EG23817A (bs)
ES (3) ES2359235T3 (bs)
FR (2) FR2790473B1 (bs)
GB (1) GB2347422A (bs)
GE (1) GEP20022676B (bs)
GT (1) GT200000017A (bs)
HK (1) HK1031223A1 (bs)
HR (2) HRP20000097B1 (bs)
HU (1) HU227629B1 (bs)
IL (1) IL134654A (bs)
IS (1) IS2116B (bs)
IT (1) IT1320763B1 (bs)
JO (1) JO2294B1 (bs)
LT (1) LTC1035115I2 (bs)
LU (1) LU92745I2 (bs)
MA (1) MA26722A1 (bs)
ME (1) ME00593B (bs)
MY (2) MY123648A (bs)
NL (1) NL300758I1 (bs)
NO (1) NO315554B1 (bs)
NZ (1) NZ502948A (bs)
OA (1) OA11680A (bs)
PA (1) PA8491101A1 (bs)
PE (1) PE20001467A1 (bs)
PL (1) PL217311B1 (bs)
PT (2) PT1394150E (bs)
RS (3) RS50194B (bs)
SE (1) SE1035115T5 (bs)
SG (1) SG91856A1 (bs)
SI (1) SI1035115T1 (bs)
SK (2) SK287911B6 (bs)
SV (1) SV2002000024A (bs)
TN (1) TNSN00032A1 (bs)
TR (1) TR200000520A3 (bs)
TW (1) TWI288746B (bs)
UA (1) UA71547C2 (bs)
UY (1) UY32314A (bs)
ZA (1) ZA200000894B (bs)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058640A2 (en) * 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
PL350427A1 (en) 1999-02-24 2002-12-16 Hoffmann La Roche Phenyl− and pyridinyl derivatives as neurokinin 1 antagonists
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
DK1103545T3 (da) * 1999-11-29 2004-03-15 Hoffmann La Roche 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 セントラル硝子株式会社 光学活性α−メチル−ビス−３、５−（トリフルオロメチル）ベンジルアミンの製造方法
DK1303490T3 (da) * 2000-07-14 2008-08-25 Hoffmann La Roche N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
EP1349541B1 (en) * 2000-12-14 2006-10-04 F. Hoffman-la Roche AG Self emulsifying lipid matrix (selm)
US6531597B2 (en) * 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
DE60220997T2 (de) * 2001-03-27 2008-03-13 Eisai R&D Management Co., Ltd. N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
BR0209151A (pt) * 2001-04-23 2004-07-13 Hoffmann La Roche Uso de antagonistas de receptor nk-1 contra hiperplasia prostática benigna
PT2266558T (pt) * 2001-06-07 2017-07-21 Analgesic Neuropharmaceuticals Llc Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
AU2002340847B2 (en) * 2001-09-10 2007-09-13 F. Hoffmann-La Roche Ag Oily thixotropic formulations
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
EP1542967A1 (en) 2002-09-20 2005-06-22 Pfizer Products Inc. Amide and sulfonamide ligands for the estrogen receptor
AU2003298034B2 (en) 2002-12-06 2011-04-21 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
CA2514037C (en) * 2003-01-31 2012-03-13 F. Hoffmann-La Roche Ag Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide
BRPI0412291A (pt) * 2003-07-03 2006-09-19 Hoffmann La Roche antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
US7288658B2 (en) * 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
ES2375134T3 (es) 2003-07-30 2012-02-27 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos.
ES2380020T3 (es) * 2004-07-06 2012-05-07 Xenon Pharmaceuticals Inc. Derivados de nicotinamida y su uso como agentes terapéuticos
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
JP5094398B2 (ja) 2004-09-20 2012-12-12 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環式誘導体およびステアロイル−ＣｏＡデサチュラーゼのメディエータとしてのそれらの使用
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
WO2006060174A1 (en) * 2004-11-15 2006-06-08 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
BRPI0606843A2 (pt) * 2005-02-22 2009-07-21 Hoffmann La Roche antagonistas de nk 1
WO2006091800A2 (en) * 2005-02-24 2006-08-31 Janssen Pharmaceutica N.V. Novel pyridine derivatives as potassium ion channel openers
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
MX2007011489A (es) * 2005-03-23 2007-10-11 Hoffmann La Roche Metabolitos para antagonistas del receptor neurokinina 1 (nk-1) para emesis.
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
WO2007021982A2 (en) * 2005-08-11 2007-02-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
SI1928886T1 (sl) 2005-09-09 2011-08-31 Glaxosmithkline Llc Derivati piridina in njihova uporaba pri zdravljenju psihotiäśnih motenj
CN103893145A (zh) 2005-09-23 2014-07-02 弗·哈夫曼-拉罗切有限公司 新型制剂
EP1945632B1 (en) * 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2554353T3 (es) 2006-04-07 2015-12-18 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CA2706920C (en) 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
RS55360B1 (sr) 2007-12-07 2017-03-31 Vertex Pharma Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
MX2012002369A (es) * 2009-08-27 2012-03-29 Glaxosmithkline Llc Formas de anhidrato de un derivado de piridina.
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
MY159393A (en) 2009-11-18 2016-12-30 Helsinn Healthcare Sa Compositions for treating centrally mediated nausea and vomiting
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2579965T3 (es) 2010-04-07 2016-08-17 Vertex Pharmaceuticals Incorporated Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
JP2013525371A (ja) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) * 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
US20140155419A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
US20140256740A1 (en) * 2011-07-29 2014-09-11 Tempero Pharmaceuticals, Inc. Compounds and methods
PL2744497T3 (pl) 2011-10-18 2016-10-31 Terapeutyczne połączenia netupitantu i palonosetronu
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP5806420B1 (ja) * 2013-11-08 2015-11-10 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
DK3424534T3 (da) 2014-04-15 2021-07-26 Vertex Pharma Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator
EP3140007A1 (en) * 2014-05-05 2017-03-15 Apicore US LLC Methods of making netupitant and intermediates thereof
TWI649307B (zh) * 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
BR112017010406B1 (pt) 2014-11-18 2021-03-09 Vertex Pharmaceuticals Incorporated processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência
KR20170122777A (ko) 2015-03-04 2017-11-06 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
ES2813596T3 (es) 2015-12-07 2021-03-24 Kissei Pharmaceutical Antagonista del receptor NK1
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
EA201891472A1 (ru) * 2015-12-22 2018-12-28 Такеда Фармасьютикал Компани Лимитед Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
CA3059418A1 (en) 2017-04-10 2018-10-18 Chase Therapeutics Corporation Nk1-antagonist combination and method for treating synucleinopathies
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
CN109384712B (zh) * 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
WO2019038656A1 (en) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
BR112020015484A2 (pt) * 2018-09-28 2021-04-27 Vanda Pharmaceuticals Inc. métodos para tratamento de um sujeito prestes a se envolver em uma atividade que implica em movimento indutor de enjoo e de um sujeito com enjoo de movimento ou pelo menos um sintoma de enjoo de movimento, composto, e, composição farmacêutica
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3902793A4 (en) * 2018-12-24 2022-09-07 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) MANUFACTURE OF A CHEMICAL COMPOUND, NEW FORM OF SALT, AND ASSOCIATED THERAPEUTIC USES
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
US20230190740A1 (en) 2020-04-03 2023-06-22 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
CN115697332A (zh) 2020-06-02 2023-02-03 尼尔医疗有限公司 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에르 위브 신규한 이소부티라미드류의 제조방법
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에르 위브 이소부티라미드 유도체의 신규한 제조방법
DE3366369D1 (en) 1982-03-17 1986-10-30 Smith Kline French Lab Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU4718093A (en) 1992-07-31 1994-03-03 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
NZ277839A (en) * 1993-12-29 1998-01-26 Merck Sharp & Dohme Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DK0764163T3 (da) 1994-06-06 2002-02-04 Warner Lambert Co Tachykinin (NK1) receptor-antagonister
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
DE69628484T2 (de) * 1995-03-24 2004-05-19 Takeda Chemical Industries, Ltd. Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
CN1168719C (zh) 1996-03-29 2004-09-29 辉瑞大药厂 6-苯基吡啶-2-基胺衍生物以及药物组合物和用途
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
PL350427A1 (en) * 1999-02-24 2002-12-16 Hoffmann La Roche Phenyl− and pyridinyl derivatives as neurokinin 1 antagonists
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
DK1103545T3 (da) * 1999-11-29 2004-03-15 Hoffmann La Roche 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide

Also Published As

Publication number Publication date
NO20000885L (no) 2000-08-25
IL134654A (en) 2011-03-31
RS50194B (sr) 2009-05-06
ES2171109B2 (es) 2003-09-16
ITMI20000328A1 (it) 2001-08-23
BR0000908B1 (pt) 2013-09-24
CA2299139A1 (en) 2000-08-24
NL300758I2 (bs) 2015-12-22
HRP20000097B1 (en) 2008-12-31
NZ502948A (en) 2001-09-28
ZA200000894B (en) 2000-08-24
US6479483B2 (en) 2002-11-12
SV2002000024A (es) 2002-01-23
SI1035115T1 (en) 2005-02-28
KR20000062599A (ko) 2000-10-25
DE60014216D1 (de) 2004-11-04
CY2015041I1 (el) 2016-06-22
BR0000908A (pt) 2000-09-12
AR062949A2 (es) 2008-12-17
TR200000520A2 (tr) 2001-06-21
IL134654A0 (en) 2001-04-30
TNSN00032A1 (fr) 2005-11-10
LTC1035115I2 (lt) 2017-04-10
HU227629B1 (en) 2011-10-28
FR15C0049I1 (fr) 2015-08-28
JP3399900B2 (ja) 2003-04-21
CZ2000609A3 (cs) 2001-01-17
GT200000017A (es) 2001-08-15
EA200000155A3 (ru) 2000-12-25
AU767048B2 (en) 2003-10-30
MY123648A (en) 2006-05-31
JP2000247957A (ja) 2000-09-12
SK2352000A3 (en) 2000-09-12
UY32314A (es) 2010-02-26
GB0003908D0 (en) 2000-04-05
GB2347422A (en) 2000-09-06
PL338598A1 (en) 2000-08-28
EA003673B1 (ru) 2003-08-28
BG104187A (en) 2000-11-30
ES2359235T3 (es) 2011-05-19
SK287912B6 (sk) 2012-03-02
JO2294B1 (en) 2005-09-12
SK287911B6 (sk) 2012-03-02
TWI288746B (en) 2007-10-21
PE20001467A1 (es) 2000-12-20
ES2171109A1 (es) 2002-08-16
PA8491101A1 (es) 2001-04-30
NO315554B1 (no) 2003-09-22
CN1270959A (zh) 2000-10-25
DK1035115T3 (da) 2005-01-24
CN1142144C (zh) 2004-03-17
MY147451A (en) 2012-12-14
CA2299139C (en) 2011-03-29
CY2015042I1 (el) 2016-06-22
FR2790473B1 (fr) 2004-04-02
HK1031223A1 (en) 2001-06-08
SE1035115T5 (sv) 2015-08-04
HUP0000748A2 (en) 2001-03-28
HUP0000748A3 (en) 2003-12-29
DK1394150T3 (da) 2011-03-21
ES2226622T3 (es) 2005-04-01
GEP20022676B (en) 2002-04-25
TR200000520A3 (tr) 2001-06-21
AU1946800A (en) 2000-08-31
CZ300596B6 (cs) 2009-06-24
HRP20080306A2 (en) 2008-11-30
CY1111317T1 (el) 2015-08-05
US20020091265A1 (en) 2002-07-11
NO20000885D0 (no) 2000-02-23
YU9500A (sh) 2002-11-15
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (en) 2015-08-31
FR2790473A1 (fr) 2000-09-08
EG23817A (en) 2007-09-19
PT1035115E (pt) 2005-01-31
ME00593B (me) 2015-08-31
PL217311B1 (pl) 2014-07-31
CY2015041I2 (el) 2016-06-22
KR100384904B1 (ko) 2003-05-22
EA200000155A2 (ru) 2000-08-28
RS20080562A (en) 2009-09-08
ITMI20000328A0 (it) 2000-02-23
EP1394150B1 (en) 2011-01-19
LU92745I2 (fr) 2015-08-17
DE10008042A1 (de) 2000-08-31
SE1035115T3 (sv) 2005-01-18
ATE277905T1 (de) 2004-10-15
BRPI0000908B8 (pt) 2021-05-25
OA11680A (fr) 2005-01-12
IS5381A (is) 2000-08-25
SG91856A1 (en) 2002-10-15
ATE496032T1 (de) 2011-02-15
PT1394150E (pt) 2011-02-17
DE60045564D1 (de) 2011-03-03
BG64554B1 (bg) 2005-07-29
MA26722A1 (fr) 2004-12-20
DE60014216T2 (de) 2006-03-02
IS2116B (is) 2006-06-15
IT1320763B1 (it) 2003-12-10
NL300758I1 (bs) 2015-12-22
BE2015C057I2 (bs) 2019-03-06
FR15C0049I2 (fr) 2016-02-12
EP1035115B1 (en) 2004-09-29
HRP20000097A2 (en) 2001-10-31
EP1035115A1 (en) 2000-09-13
HU0000748D0 (en) 2000-04-28
US6297375B1 (en) 2001-10-02
HRP20080306B1 (hr) 2015-01-30
UA71547C2 (uk) 2004-12-15
AR029614A1 (es) 2003-07-10
EP1394150A1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
MEP5709A (en) 4-phenyl-pyridine derivatives
WO2000050398A3 (en) Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
BR0008494A (pt) Derivados de 3-fenilpiridina e seu uso como antagonista do receptor de nk-1
BRPI0513281A (pt) composto ou compostos, medicamentos, uso de pelo menos um composto, método para o tratamento terapêutico e/ou profilático de um mamìfero, e, processo para a produção de um composto
EA200300072A1 (ru) Карбаматы, полученные из арилалкиламинов
RS50932B (sr) N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
NO20020823L (no) Heteropolysykliske forbindelser og deres anvendelse som metabotropiske glutamatreseptorantagonister
PE20020332A1 (es) Derivados de 4-fenil-piridina como antagonistas de receptores de neuroquinina nk-1
EA200300619A1 (ru) Серотонинергические средства
CO5080744A1 (es) Ligandos de alta afinidad para el receptor de nociceptina orl-1
YU85001A (sh) Derivati 5-fenil-pirimidina
NO883279D0 (no) Benzopyranderivater.
YU84901A (sh) Derivati 4-fenil-pirimidina
DE60016786D1 (de) Bicyclische vasopressin-agoniste
EA200001184A1 (ru) Фенилсульфонамидфенилэтиламины, полезные в качестве допаминовых рецепторов
ES2104370T3 (es) Derivados de (arilalquilaminobencil)aminopropionamidas sustituidas, su preparacion y utilizacion.
EA199900043A1 (ru) ПРОИЗВОДНЫЕ ПИРИДИЛКАРБАМОИЛИНДОЛИНОВ В КАЧЕСТВЕ АНТАГОНИСТОВ 5-НТ2с-РЕЦЕПТОРОВ
ATE215083T1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden
DE59814233D1 (de) Indolmethyl-N,N'-bisacylpiperazine als Neurokininrezeptorantagonisten